^
BIOMARKER:

MGMT promoter methylation

i
Other names: MGMT, Methylated-DNA--protein-cysteine methyltransferase, 6-O-methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase
Entrez ID:
Related biomarkers:
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/14/2022
Initiation :
08/06/2020
Primary completion :
08/23/2024
Completion :
08/23/2024
PD-L1 • IDH1 • MGMT
|
IDH1 R132H • MGMT promoter methylation • IDH1 R132
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 2
Weill Medical College of Cornell University
Not yet recruiting
Last update posted :
01/07/2022
Initiation :
01/01/2022
Primary completion :
12/01/2023
Completion :
12/01/2024
MGMT
|
MGMT promoter methylation
|
metformin • paxalisib (GDC-0084)
Phase 3
Denovo Biopharma LLC
Recruiting
Last update posted :
12/21/2021
Initiation :
12/16/2020
Primary completion :
06/01/2025
Completion :
06/01/2025
MGMT
|
MGMT promoter methylation
|
temozolomide • Kinenza (enzastaurin)
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Not yet recruiting
Last update posted :
12/01/2021
Initiation :
12/01/2021
Primary completion :
12/01/2022
Completion :
12/01/2026
MGMT
|
MGMT promoter methylation
|
temozolomide • capecitabine
Phase 3
NRG Oncology
Not yet recruiting
Last update posted :
10/27/2021
Initiation :
05/06/2022
Primary completion :
08/08/2026
Completion :
08/08/2031
IDH1 • MGMT
|
IDH1 R132H • MGMT promoter methylation • IDH1 R132
|
temozolomide • lomustine
Phase N/A
Abramson Cancer Center of the University of Pen...
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
01/01/2022
Primary completion :
06/30/2026
Completion :
06/30/2026
MGMT
|
MGMT promoter methylation • IDH wild-type
Phase 2
photonamic GmbH & Co. KG
Recruiting
Last update posted :
09/30/2021
Initiation :
09/03/2021
Primary completion :
03/01/2023
Completion :
03/01/2027
MGMT • CD4
|
MGMT promoter methylation • IDH wild-type
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Active, not recruiting
Last update posted :
09/24/2021
Initiation :
03/25/2019
Primary completion :
09/30/2021
Completion :
02/01/2022
MGMT
|
MGMT promoter methylation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide
Phase 2
Cecilia Soderberg-Naucler
Recruiting
Last update posted :
09/13/2021
Initiation :
09/04/2019
Primary completion :
08/31/2024
Completion :
08/31/2024
MGMT
|
MGMT promoter methylation • IDH wild-type
|
temozolomide • Valcyte (valganciclovir)
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Not yet recruiting
Last update posted :
09/10/2021
Initiation :
11/01/2021
Primary completion :
11/01/2024
Completion :
11/01/2024
MGMT • CEACAM5
|
MGMT promoter methylation
|
temozolomide • irinotecan
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Completed
Last update posted :
09/09/2021
Initiation :
09/01/2014
Primary completion :
07/30/2019
Completion :
07/30/2019
KRAS • MGMT
|
MGMT promoter methylation
|
5-fluorouracil • temozolomide • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
IFOM, The FIRC Institute of Molecular Oncology
Recruiting
Last update posted :
08/25/2021
Initiation :
01/23/2019
Primary completion :
09/01/2022
Completion :
12/01/2022
TMB • MGMT
|
MSI-H/dMMR • MGMT promoter methylation
|
Keytruda (pembrolizumab) • temozolomide
Phase 2
AHS Cancer Control Alberta
Not yet recruiting
Last update posted :
08/20/2021
Initiation :
12/01/2021
Primary completion :
01/01/2031
Completion :
01/01/2031
MGMT
|
MGMT promoter methylation
|
temozolomide
Phase 1/2
Nerviano Medical Sciences
Not yet recruiting
Last update posted :
08/12/2021
Initiation :
09/30/2021
Primary completion :
12/31/2024
Completion :
05/30/2025
IDH1 • IDH2 • MGMT
|
MGMT promoter methylation • IDH wild-type
|
temozolomide • lomustine • NMS-293
Phase 2/3
Laminar Pharmaceuticals
Recruiting
Last update posted :
07/19/2021
Initiation :
12/01/2019
Primary completion :
04/30/2022
Completion :
10/30/2023
IDH1 • MGMT
|
MGMT promoter methylation • IDH wild-type
|
temozolomide • Minerval (2-hydroxyoleic acid)
Phase 2
European Organisation for Research and Treatmen...
Not yet recruiting
Last update posted :
06/25/2021
Initiation :
12/01/2021
Primary completion :
05/01/2024
Completion :
12/01/2024
IDH1 • MGMT
|
IDH1 R132H • MGMT promoter methylation • IDH1 R132
|
lomustine • Nplate (romiplostim)
Phase 1/2
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
06/16/2021
Initiation :
02/25/2009
Primary completion :
07/06/2018
Completion :
01/20/2021
MGMT
|
MGMT promoter methylation
|
temozolomide • carmustine • Mozobil (plerixafor) • Neupogen (filgrastim) • TevaGrastim (filgrastim biosimilar) • peripheral blood stem cell transplantation
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
05/21/2021
Initiation :
11/01/2014
Primary completion :
01/01/2025
Completion :
01/01/2026
MGMT • IFNG
|
MGMT promoter methylation
|
Keytruda (pembrolizumab) • temozolomide • Neo Vax (NEO-PV-01)
Phase 
National Cancer Institute, Naples
Active, not recruiting
Last update posted :
05/19/2021
Initiation :
01/20/2021
Primary completion :
01/01/2022
Completion :
01/01/2022
MGMT
|
MGMT promoter methylation
|
dacarbazine
Phase 
Maastricht Radiation Oncology
Active, not recruiting
Last update posted :
04/30/2021
Initiation :
04/10/2021
Primary completion :
09/01/2021
Completion :
01/01/2022
MGMT
|
MGMT promoter methylation
Phase 3
Universitätsmedizin Mannheim
Recruiting
Last update posted :
04/30/2021
Initiation :
12/09/2016
Primary completion :
12/01/2023
Completion :
03/01/2024
MGMT
|
MGMT promoter methylation
|
temozolomide
Phase 2/3
VU University Medical Center
Recruiting
Last update posted :
04/19/2021
Initiation :
08/31/2018
Primary completion :
01/01/2022
Completion :
01/01/2022
MGMT
|
MGMT promoter methylation
|
Sutent (sunitinib) • lomustine
Phase N/A
Neuromed IRCCS
Recruiting
Last update posted :
04/12/2021
Initiation :
06/26/2019
Primary completion :
06/26/2019
Completion :
12/30/2021
IDH1 • MGMT • ATRX • GFAP
|
MGMT promoter methylation
Phase 1
University of Pennsylvania
Completed
Last update posted :
03/03/2021
Initiation :
03/11/2019
Primary completion :
02/27/2021
Completion :
02/27/2021
EGFR • MGMT • TERT
|
EGFR amplification • MGMT promoter methylation • TERT promoter mutation • EGFRvIII expression • TERT mutation • IDH wild-type
|
Keytruda (pembrolizumab) • CART-EGFRvIII T cells
Phase 2
Daniela A. Bota
Recruiting
Last update posted :
02/23/2021
Initiation :
05/21/2020
Primary completion :
06/01/2023
Completion :
06/01/2023
IDH1 • MGMT • TERT • ATRX
|
IDH1 mutation • MGMT promoter methylation • IDH1 mutation + MGMT promoter methylation
|
Avastin (bevacizumab)
Phase 1b
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Recruiting
Last update posted :
02/19/2021
Initiation :
01/01/2021
Primary completion :
06/01/2022
Completion :
01/01/2023
BRAF • MGMT
|
MGMT promoter methylation
|
Avastin (bevacizumab) • 5-fluorouracil • temozolomide • irinotecan • leucovorin calcium
Phase N/A
Istituto Clinico Humanitas
Completed
Last update posted :
10/01/2020
Initiation :
07/01/2015
Primary completion :
12/31/2018
Completion :
12/31/2018
IDH1 • MGMT
|
IDH1 mutation • MGMT promoter methylation
Phase 2
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
09/21/2020
Initiation :
06/01/2006
Primary completion :
10/01/2013
Completion :
08/01/2015
MGMT
|
MGMT promoter methylation
|
Avastin (bevacizumab) • temozolomide
Phase 2
Jonsson Comprehensive Cancer Center
Withdrawn
Last update posted :
07/24/2020
Initiation :
12/01/2019
Primary completion :
12/01/2020
Completion :
12/01/2022
PD-L1 • MGMT
|
MGMT promoter methylation
|
Opdivo (nivolumab) • DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)
Phase 2
Heinrich-Heine University, Duesseldorf
Recruiting
Last update posted :
05/27/2020
Initiation :
03/06/2018
Primary completion :
09/06/2022
Completion :
06/06/2023
MGMT
|
MGMT promoter methylation • IDH wild-type
|
temozolomide
Phase 2
Memorial Sloan Kettering Cancer Center
Withdrawn
Last update posted :
12/12/2019
Initiation :
03/13/2019
Primary completion :
03/01/2021
Completion :
03/01/2021
MGMT
|
MSI-H/dMMR • MGMT promoter methylation
|
Opdivo (nivolumab) • temozolomide
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
11/22/2019
Initiation :
07/08/2011
Primary completion :
11/15/2019
Completion :
11/15/2019
MGMT
|
MGMT promoter methylation
|
Avastin (bevacizumab)
Phase 1
Center Trials & Treatment Europe
Not yet recruiting
Last update posted :
09/17/2019
Initiation :
12/10/2019
Primary completion :
09/15/2020
Completion :
11/15/2020
IDH2 • MGMT
|
IDH2 mutation • MGMT promoter methylation
|
temozolomide
Phase 1
Leaf Vertical Inc.
Not yet recruiting
Last update posted :
02/26/2019
Initiation :
06/01/2019
Primary completion :
09/30/2019
Completion :
12/31/2020
MGMT
|
MGMT promoter methylation
|
temozolomide • cannabidiol (BRCX014)
Phase 
Istituto Ortopedico Rizzoli
Recruiting
Last update posted :
05/31/2018
Initiation :
04/15/2014
Primary completion :
12/31/2018
Completion :
06/30/2019
MGMT
|
MGMT promoter methylation
|
temozolomide • irinotecan
Phase N/A
Tang-Du Hospital
Enrolling by invitation
Last update posted :
04/05/2017
Initiation :
01/01/2017
Primary completion :
04/10/2017
Completion :
03/03/2018
IDH1 • IDH2 • MGMT • ATRX • DHCR7
|
MGMT promoter methylation
Phase 1
AHS Cancer Control Alberta
Withdrawn
Last update posted :
02/22/2016
Initiation :
07/01/2008
Primary completion :
01/01/2010
MGMT
|
MGMT promoter methylation
|
temozolomide • dichloroacetate
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
11/18/2015
Initiation :
01/01/2005
Primary completion :
06/01/2008
Completion :
06/01/2008
MGMT • IL2
|
MGMT promoter methylation
|
temozolomide
Phase 2
Prof. Dr. Wolfgang Wick
Completed
Last update posted :
08/15/2014
Initiation :
09/01/2009
Primary completion :
06/01/2013
Completion :
06/01/2013
MGMT
|
MGMT promoter methylation
|
temozolomide